

Using Genome Editing to Engineer Universal Platelets

Moyra Lawrence^{1,2}, Annett Mueller^{1,2}, Cedric Ghevaert^{1,2,*}.

¹Department of Haematology, University of Cambridge and NHS Blood and Transplant, Long Road, Cambridge CB2 0PT, UK

²Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Tennis Court Road, Cambridge CB2 1QR, UK

*Correspondance: cg348@cam.ac.uk

Abstract

Genome editing technologies such as Zinc Finger nucleases, TALENS and CRISPR/Cas9 have recently emerged as tools with the potential to revolutionise cellular therapy. This is particularly exciting for the field of regenerative medicine, where the large-scale, quality controlled editing of large numbers of cells could generate essential cellular products ready to move towards the clinic. This review details recent progress towards generating HLA Class-I null platelets using genome editing technologies for beta-2-microglobulin deletion, generating a universally transfusable cellular product. In addition, we discuss various methods for megakaryocyte (MK) production from human pluripotent stem cells and subsequent platelet production from the MKs. As well as simply producing platelets, differentiating MK cultures can enable us to understand megakaryopoiesis *in vivo* and take steps towards ameliorating bleeding disorders or deficiencies in MK maturation in patients. Thus by intersecting both these areas of research, we can produce optimised differentiation systems for the production of universal platelets, thus offering a stable supply of platelets for difficult-to-match patients and providing areas with transmissible disease concerns or an unpredictable supply of platelets with a steady supply of quality controlled platelet units.

Introduction

Although genome editing technologies such as Zinc Fingers and TALENS have been around for some time, it is the repurposing of the bacterial CRISPR/Cas9 defence system that has recently provided an efficient, affordable and adaptable method for rapid and reproducible gene editing^{1,2}. This is particularly exciting for the field of regenerative medicine, where large-scale, quality controlled editing of large numbers of cells could generate essential cellular products ready to move towards the clinic. In addition to being able to knock specific genes out, the CRISPR/Cas9 system also enables the insertion of relatively large constructs into cells^{3,4}, enabling the production of recombinant proteins from edited cells, or even more ambitiously, the production of cells for the targeted release of therapeutic proteins at specific sites in the body.

Platelets and transfusions

Platelets are one of the few cell types which have no nucleus, which makes them one of the most ideal cell types for transfusion after gene editing. In addition, platelets retain their functionality after irradiation, reducing the likelihood of nucleated stem or progenitor cells surviving in the platelet unit. There is also evidence to suggest that mature megakaryocytes can produce platelets effectively, even after irradiation⁵. Platelets could be one of the safest first-in-human stem cell-derived products for transfusion and provide us with an avenue to safely use gene editing methodology for the advent of new cellular products and medicines.

Platelets are 2-4µm anucleate discoid cells in the circulation^{6,7} and are responsible for clotting. The deficiency of platelets is known as thrombocytopenia and it can have diverse causes, including inherited and acquired bone marrow deficiency, chemotherapy, radiotherapy, trauma, major surgery, severe infection or hypercoagulation⁸. Patients with thrombocytopenia are susceptible to severe bleeding events, and to prevent this they are transfused with donor platelets. Platelet units are generally ABO and Rhesus D matched^{8,9} to avoid alloimmunisation against RhD from the few red cells present in the platelet unit or lysis from anti-A/anti-B present in the plasma into which platelets are suspended. However, some patients develop antibodies against antigens present on the surface of platelet themselves, namely HLA Class I and Human Platelet Antigens (or in rare cases against auto- or drug-induced antigens)¹⁰ (Figure 1). Among these, antibodies against HLA Class I are the most common¹⁰⁻¹². Patients generally produce these antibodies as a response to previous transfusions or pregnancies. However, a certain proportion of individuals in the general population also have antibodies against other HLA Class-I types. In one study, 17% of donors who had not been either pregnant or previously transfused had antibodies against HLA Class I¹³, potentially posing a risk of rejection during standard platelet transfusion

Providing matched platelet units for all thrombocytopenic patients is difficult because platelet units have a very short shelf life of only 5 to 7 days at room temperature. There are times of year where matched units are difficult to find, and other times when units accumulate, wasting the resources used to collect and store them. The logistical challenge of providing HLA Class-I matched units for alloimmunised patients leads to significant costs, estimated to be in the region of five times the usual cost of platelet provision^{10,14}. If platelets could be produced *in vitro* from "HLA Class-I null" seed cells, this would alleviate the need to match platelet units and provide a supply of universal platelets for transfusion.

Megakaryocytes

In vivo, platelets are produced by multinucleated cells which are known as megakaryocytes (MKs)¹⁵. These cells make up 0.01-0.03% of nucleated bone marrow cells¹⁶ and are large cells of 5-50µm in diameter with a mean diameter of 19.4 +/-3 µm^{6,17}. Megakaryocytes differentiate from haematopoietic stem cells (HSCs) in the bone marrow¹⁸. As they mature, the multiple nuclei of the megakaryocyte are produced by endomitosis¹⁸. After becoming multinucleate, megakaryocytes then begin cytoplasmic maturation¹⁸ during which they produce a membrane demarcation system, which is an extension of their cell membrane that invaginates into the cell. This forms the production centre for platelets¹⁹. Proplatelet extensions or large fragments of MKs emanate from the membrane demarcation system into the bone marrow sinusoids, where the blood flow buds off nascent platelets from the tip of each or breaks up larger fragments of MKs^{20,21} (Figure 2). Each megakaryocyte is estimated to produce 100-1000 platelets and the collective production of platelets is estimated at 1-2 x 10¹¹ each day^{18,20}. Platelets survive for 7-10 days in the circulation, before being removed by the spleen¹⁸.

Producing megakaryocytes *in vitro*.

Megakaryocytes are found in very small numbers in the bone marrow, thus they cannot be harvested and transplanted from one person to another. They differentiate from haematopoietic stem cells (HSCs), which are also present in small numbers the bone marrow.

HSCs can be mobilised from peripheral blood or harvested directly from the bone marrow or from cord blood.^{22,23} HSCs can be transplanted, but they generate the entire blood system and we have no way of directing their differentiation solely towards MKs *in vivo*. Therefore, to generate universal platelets, rather than transplanting MKs or their progenitors, we need to produce MKs *in vitro* and use these for the production of platelet units which we can then transfuse.

HSCs can be differentiated with a cytokine cocktail to form mature MKs which were capable of platelet production²⁴. However, HSCs cannot be expanded *in vitro* and their MK production efficiency falls well below that required for the generation of clinically relevant platelet numbers. In addition, HSC isolation requires either invasive bone marrow sampling or the treatment of donors with granulocyte colony stimulating factor for several days before donation. It would be beneficial to turn towards a cell type which could be easily generated and expanded *in vitro*.

Induced pluripotent stem cell (iPSC) lines represent a possible alternative source of seed cells. While overcoming the potential ethical issues associated with human embryonic stem cells (hESCs), iPSCs can produce all differentiated cell types and are infinitely expandable *in vitro*, overcoming the need to repeatedly harvest primary cells. They can also be gene edited and quality controlled, generating HLA-Class I knockout lines for the generation of universal platelets.

There are several systems which have been developed for the production of MKs from pluripotent stem cells (Figure 3). First of all, cytokine cocktails [invariably containing thrombopoietin (TPO)] can be applied to pluripotent cells to mirror MKs' *in vivo* developmental trajectory and shepherd the cells towards megakaryocyte differentiation²⁵⁻²⁷. This is known as "directed differentiation". Directed differentiation can be aided by feeder layers such as OP9 stromal cells^{28,29} upon which ESCs produce sac-like structures³⁰. These sac-like structures contain large amount of progenitors which can differentiate into mature MKs. Output can be increased by the treatment of differentiating sacs with VEGF³⁰.

Progressing away from feeders and undefined conditions, megakaryocytes were then differentiated from hESCs using TPO, SCF and IL11 in defined media conditions³¹. These MKs were produced in large numbers at around 118 per starting iPSC and could also produce platelets that contributed to clot formation in a mouse model. A second group also generated MKs from hESCs without feeders in defined conditions using an embryoid body based protocol³². Interestingly, these could also fragment to generate platelet-like particles.

Directed differentiated methods alleviate the risk to patients from transduced or transformed cell products, as the cells are unmodified²⁵. Directed differentiation approaches can also be combined with the use of bioreactors, as the hPSCs can be loaded onto laminin-coated microcarrier beads and the cell suspension stirred as they differentiate into MKs. This can increase output per starting hPSC⁵. However, the cytokine dosage required for these protocols remains high, increasing the production costs of any potential cellular product. In addition, directed differentiation protocols are still often hampered by low production efficiency.

Because of this low efficiency, groups aimed to increase the efficiency of MK differentiation with viral transgenes. Platelet release from *in vitro* derived MKs was increased after transduction with CMYC³³. Thus the idea of directing cell fate with viral transgenes began to gain a foothold. Another group generated cells with megakaryocyte erythroid progenitor (MEP)-associated surface marker expression after transducing hESCs which GATA2, TAL1 and LMO2³⁴. Transducing ESCs with ETV2 and GATA2 generated cells which could form megakaryocyte-like colonies in colony forming assays³⁴.

The Eto group then extended their ES-Sac protocol to include viral transgenes. After the generation of the sac-like structures, haematopoietic progenitor cells were isolated and immortalised by viral transduction with CMYC, BMI1 and BCLXL, enabling expansion for up to 5 months after transformation³⁵. Upon removal of the viral transgenes, the cells matured and produced platelets, demonstrating that despite the immortalisation, the MKs produced remain functional. However, an important caveat of this approach is the potential for tumorigenesis. The authors observe that after prolonged culture, some clones acquired karyotypic anomalies which could generate leukaemia in recipient mice. Because the safety controls in place for the production of platelets *in vitro* would probably involve irradiation of the cells before transfusion and BMI1 overexpression could rescue cells from apoptosis³⁶, this presents a possible safety concern.

Work in our lab has generated a protocol for the generation of expandable MKs cultures without the need for transformation³⁷. This is achieved by the transduction of hiPSCs with GATA1, TAL1 and FLI1. Within 20 days in only two cytokine combinations, these cells generate a pure population of mature megakaryocytes which can produce platelets *in vitro*⁶. These cultures can be maintained for up to 120 days in culture without losing their platelet production abilities and can be frozen and rethawed.

Bioreactors for the generation of platelets from *in vitro* produced megakaryocytes.

After the generation of mature megakaryocytes from human pluripotent stem cells, the megakaryocytes need to be fragmented to form platelets. *In vivo*, this is done as or after the megakaryocyte approaches the lumen of the bone marrow sinusoids and buds through into the circulation. Various models have been proposed through which megakaryocytes form platelets^{18,20,21}, however consensus in the field would suggest that blood flow through the bone marrow drives the disruption of the megakaryocyte and the formation of platelets^{18,21,38}. To achieve this *in vitro*, bioreactors have been designed to mimic the shear the blood flow would exert on megakaryocytes *in vivo*. These vary significantly in design. A recent publication by the Eto group describes a large stirred bioreactor which uses the vertical movements of large paddles to fragment mature megakaryocytes³⁹. Microfluidic devices have also been designed which adhere megakaryocytes to a fenestrated membrane using fluid flow⁴⁰. Their membranes are then forced through the fenestrated membrane and budded off, forming platelets. A third method of deriving platelets from their parent MK involves loading a sponge of defined pore sizes with the mature megakaryocytes^{6,41}. Fluid can then be pumped through the sponge to encourage the megakaryocytes to release platelets, which due to their smaller size can flow freely out of the sponge. Finally, a fourth model has been designed which loads the megakaryocytes onto a silk sponge fitted with multiple narrow channels, mimicking intramarrow blood vessels. MKs adhere in the multiple channels and bud off their platelets in

response to media flow⁴². Almost universally, thus, these bioreactors utilise fluid flow to produce platelets. Additionally, the sponge systems are amenable to functionalisation in order to mimic the chemical environment of the bone marrow. Most of the systems, apart from the first, also separate the parent megakaryocytes from their daughter platelets, ensuring the lack of nucleated cells in the final product. In the first system, separation between platelets and MKs is done by centrifugation which may adversely affect the platelets' quality as a transfusion product.

HLA Class I deletion

The HLA system is a series of closely linked genes which together are responsible for the presentation of antigens to the immune system and immune surveillance of the body⁴³. HLA Class I genes include the classical HLA-A, -B and -C, the non-classical HLA-E, -F and -G and MHC Class I chain-related MICA and MICB. Classical HLA Class I proteins are expressed on most nucleated cells whereas the non-classical and associated proteins have more restricted expression ranges⁴³. HLA Class I presents antigens to CD8⁺ cytotoxic T lymphocytes. HLA-A, -C, -E and -G can also present to natural killer (NK) cells, $\gamma\delta$ T cells and CD8⁺ T cells. Interestingly, most anti-platelet antibodies generated by patients who become refractory to transfusion are against HLA-A and -B¹⁰, thus these represent a possible target for deletion with an aim to the transfusion of at-risk patients.

For correct assembly on the cell surface, HLA Class I requires β 2 microglobulin. In order to delete all HLA Class I without targeting all the genes separately, β 2 microglobulin can be disrupted. This was first carried out by the lentiviral transduction of iPSCs with shRNA²⁷. This resulted in an 87% reduction in the transcript levels of β 2 microglobulin without compromising the cells' expression of pluripotency-associated markers. These cells were then differentiated into MKs by three sequential cytokine cocktails. Differentiation efficiency was not adversely affected by the reduction of HLA Class I. Furthermore, the platelets produced from these HLA Class I deficient MKs were functional and survived longer in a mouse model for platelet refractoriness than control platelets. This was the first indication that HLA Class I deletion is both possible and beneficial for human *in vitro*-produced platelets. However, with this system, HLA Class I levels were reduced but the protein was not completely absent. The absence of HLA Class I is reported to cause cytotoxicity by the activation of Natural Killer (NK) cells⁴⁴. Therefore, it was not clear whether the minimal residual levels of HLA Class I were sufficient to block this destruction.

HLA Class I knockdown has also been carried out on CD34⁺ stem cells in order to generate HLA Class I knockdown MKs^{45,46}. Again, this was carried out by transduction of the cells with a lentivirus encoding anti β 2-microglobulin shRNA. These CD34⁺ cells could then be differentiated into megakaryocytes, interestingly at higher efficiency than controls⁴⁶. They also generated higher numbers of platelets. Crucially, HLA Class I knockdown (KD) cells could evade antibody dependent cellular cytotoxicity *in vitro*, indicating that they might escape immune surveillance better than control cells⁴⁵. To investigate the immune response to these cells *in vivo*, the group then generated a mouse model for platelet survival. MKs from KD and control CD34⁺ cells were then injected into NOD/SCID/IL2R γ C^{-/-} (NSG) mice. Both KD and control MKs could produce platelets *in vivo*, however upon the addition of human anti-HLA Class I antibodies, control platelets were destroyed whereas HLA Class I KD platelets survived at higher levels for up to 11 days⁴⁵. This demonstrates the utility of HLA Class I deletion or

reduction for transfusion, as it could enable the survival of transfused platelets in the circulation, despite circulating antibodies against HLA Class I. However, NSG mice will not have human NK cells, and this poses a problem for the proper assessment of NK-mediated destruction of HLA Class I deleted cells. HLA Class I expression in the CD34⁺ cells used in these studies was 85% of control levels, thus residual protein levels could inhibit the activation of NK cells if the cells were exposed to a full human immune system⁴⁶. However, the levels of HLA Class I which are required to appease NK cells remained to be tested.

In order to address this, the authors then turned to a model rat system. They silenced rat HLA Class I in fibrosarcoma cells by transducing them with lentivirus encoding shRNA against $\beta 2$ microglobulin⁴⁷. These were then transplanted into rats. Cells which had silenced HLA Class I formed larger tumours than control cells, illustrating the idea that HLA Class I removal enables cells to evade immune recognition. HLA Class I KD tumours were infiltrated with less CD4⁺ and CD8⁺ T cells than controls, indicating that the cells elicited poorer lymphocyte activation, which they also demonstrated using a T cell proliferation assay. Interestingly, HLA Class I silenced tumours did not have increased NK cell infiltration, indicating that the reduction in HLA Class I does not activate the 'missing self' immune response^{47,48}. *In vitro* assays also suggested that NKs do not recognise fibroblasts expressing more than 10% of the normal levels of HLA Class I and as these cells had 15% HLA Class I expression remaining, they could escape NK cell recognition.

To mitigate the risk that HLA Class I null cells could be destroyed by NK cells, it could be useful to express cell surface receptors which activate inhibitory NK receptors. For example, HLA-E binds to NKG2A/CD94 and protects HLA-E-expressing cells from NK-mediated lysis⁴⁹⁻⁵¹. Human HLA-E was expressed in pig cells, which then protected them from lysis *in vitro* by human NK cells, indicating that HLA-E overexpression could be a complementary strategy to protect HLA-A, -B and -C null cells from NK-mediated lysis⁵². HLA-G overexpression has also been carried out in hESCs and this also protected ESC-derived epithelial progenitors from NK-mediated lysis *in vitro*⁵³. However, HLA-E and -G require $\beta 2$ microglobulin for assembly of their membrane bound forms, therefore using these immune modulators in HLA Class I KO cells would require $\beta 2$ microglobulin re-expression, fused to HLA-E or -G^{49,54,55}.

As gene editing techniques advanced, it became more straightforward to produce $\beta 2$ microglobulin KO cells, which could then be used for the differentiation of MKs. This was first done in 2014, where the authors used TALE-nucleases to knockout $\beta 2$ microglobulin by the disruption of exon 2²⁵. A cytokine-mediated directed differentiation approach to differentiate $\beta 2$ microglobulin^{-/-} iPSCs into MKs. The platelets remained HLA Class I null and were activated in response to thrombin to a similar extent to controls²⁵. This indicates that HLA Class I null platelets can be produced and remain functional. However, it remains to be demonstrated whether these HLA Class I null cells are recognised by the human immune system and specifically whether they might be targeted for destruction by NK cells. To address this, human HLA Class I KO platelets should be assessed in a humanised mouse model which would enable the interaction of *in vitro*-derived platelets with human NK cells *in vivo*⁵⁶. This would be the first step towards the generation and transfusion of universal platelets.

Quality control of edited cellular products

The advent of genome engineering also creates a new landscape for the regulation and quality control of cellular products. Cells edited with CRISPR/Cas9 need to be assessed for safety before approaching clinical trials. Gene editing systems (Summary in Figure 4), as well as the clonal selection necessary to start master cell banks of edited iPSCs can introduce potentially deleterious mutations into pluripotent stem cells. For example, it has recently been demonstrated that human pluripotent stem cell cultures can acquire p53 mutations during extended culture⁵⁷. These mutations may allow cells to outcompete their neighbours, eventually taking over the culture⁵⁸.

In order to address these concerns, strict quality control must be carried out on the starting cell population, and repeated at regular intervals during differentiation. Current work in the field is addressing which techniques may be best for efficient and sensitive quality control. Karyotyping may be useful to identify large abnormalities, whereas qPCR of key loci, fluorescence in situ hybridisation and droplet PCR could be useful to identify the emergence of smaller mutations⁵⁹. Combining this with regular analysis of cancer-associated single nucleotide polymorphisms by SNP array could enable the early detection of cancer- and proliferation-associated mutations⁶⁰. Pluripotent starting cells should be subjected to a highly stringent quality control step, including not only karyotyping but more detailed analyses analysing genome integrity such as SNP arrays, FISH or whole genome sequencing analysis. The final MK product should also be strictly controlled, possibly including SNP arrays, karyotype, clonogenicity assays and the analysis of a panel of markers by flow cytometry.

In addition, there is much concern about potential off-target effects of CRISPR/Cas9, many of which can be mitigated by the use of paired Cas9 nickases⁶¹ and the use of proteins instead of nucleic acids⁶² but some of which may still be of concern. The starting pluripotent stem cell also needs to be available at clinical grade, posing an addition hurdle to line selection for differentiation⁶³. Finally, the transplant or transfusion of a human recipient with an edited cellular product represents an enormous safety concern for regulators, particularly where the cell type or its progenitor or stem cell is long-lived and has the potential to colonise the body or generate tumours. Cells should be terminally differentiated and efficiency should be regularly analysed, to exclude proliferating progenitors from any potential cellular product. Additional layers of security can also be built into the system by the use of suicide genes. For example, iPSCs can be transduced with a Caspase 9 which is expressed by treating cells with a chemical inducer⁶⁴. Tumours from the cells can then be eradicated by treating cells with the chemical inducer. Crucially, this is effective *in vitro* as well as *in vivo*, providing a rapid method to remove any escaping cells, if necessary.

In conclusion, quality control of both the starting pluripotent cell type and the final differentiated cell product are critical steps in providing a safe and consistent product. Much work remains to be done on determining which quality controls need to be put in place and the sooner industry standards are set, the sooner *in vitro* platelets can progress towards the clinic. Many cellular products are already well advanced towards clinical trial⁶⁵ and defining quality control standards remains a critical step in this process.

Perspectives

Work by multiple groups has demonstrated the robust and reproducible differentiation of mature MKs from many cell sources including CD34⁺ stem cells from peripheral blood, hESCs

and hiPSCs. MKs have also been transdifferentiated from fibroblasts⁶⁶. Progress has also been made towards the reduction or deletion of β 2-microglobulin with a view to generating platelets with reduced or absent HLA Class I. However, it still remains to be addressed whether *in vitro* derived HLA Class I KO platelets can survive the human immune system, and furthermore whether HLA Class I deletion is the best path towards a universal transfusion product⁶⁷. Because they degranulate at the site of injury, platelets represent an unrivalled method of targeting drugs after haemorrhage or infarction. The systems we use to generate them also provide us with a key insight into processes which occur deep in the bone marrow during MK maturation. Analysis of differentiating MK cultures can enable us to understand megakaryopoiesis *in vivo* and take steps towards ameliorating bleeding disorders or deficiencies in MK maturation in patients. The path towards the clinic is a shorter one for platelets than for many other cellular products, however much work still needs to be done before we can generate universally transfusable platelets.

Summary points

- Megakaryocytes can be reproducibly and efficiently differentiated from human pluripotent stem cells, enabling us to produce platelets *in vitro*.
- The knockdown or deletion of β 2 microglobulin can generate HLA Class I knockdown or knockout megakaryocytes, which can produce platelets for universal transfusion.
- Much optimisation is taking place on methods of differentiation, with a particular aim to decrease cytokine requirements, increase the generation of mature megakaryocytes and reduce culture volume for the production of platelet units.
- Standard quality control procedures are needed for the production of cellular products and the control of gene editing effects need to be factored into all cellular therapy production protocols.

Figures

Figure 1: Immune-recognised platelet antigens. Antigens posing a risk for alloimmunisation after platelet transfusions. Common antigens causing the rejection of platelets in Caucasian populations are shown in bold.

Figure 2: Megakaryocyte differentiation *in vivo*. Schematic of megakaryocyte differentiation from HSCs in the bone marrow. As they differentiate, MKs move towards the bone marrow sinusoids where they adhere to endothelial cells and extend proplatelet extensions or entire cell fragments, budding platelets off into the circulation.

Figure 3: Summary of *in vitro* megakaryocyte differentiation protocols. Schematic of optimised protocol for the differentiation of megakaryocytes from pluripotent stem cells, either by directed differentiation using cytokines alone, or with the aid of transgenes in addition to cytokines.

Figure 4: Methods of gene editing. Gene editing methodologies with possible uses to generate universal platelets. Gene targeting is shown in the green panel, which is inefficient in most cell types and requires the generation of DNA breaks. Nucleases which can generate these targeted breaks are shown in the orange panel.

Funding: UK Regenerative Medicine Platform and the Pluripotent and Engineered Cell Hub. Research in the laboratory is supported by core funding from Wellcome and MRC to the Wellcome-MRC Cambridge Stem Cell Institute.

References

- 1 Cong, L. *et al.* Multiplex genome engineering using CRISPR/Cas systems. *Science (New York, N.Y.)* **339**, 819-823 (2013).
- 2 Mali, P. *et al.* RNA-guided human genome engineering via Cas9. *Science* **339**, 823-826 (2013).
- 3 Cong, L. *et al.* Multiplex genome engineering using CRISPR/Cas systems. *Science* **339**, 819-823 (2013).
- 4 Yang, H. *et al.* One-step generation of mice carrying reporter and conditional alleles by CRISPR/Cas-mediated genome engineering. *Cell* **154**, 1370-1379 (2013).
- 5 Eicke, D. *et al.* Large-scale production of megakaryocytes in microcarrier-supported stirred suspension bioreactors. *Sci Rep* **8**, 10146, doi:10.1038/s41598-018-28459-x (2018).
- 6 Shepherd, J. H. *et al.* Structurally graduated collagen scaffolds applied to the ex vivo generation of platelets from human pluripotent stem cell-derived megakaryocytes: Enhancing production and purity. *Biomaterials* **182**, 135-144, doi:10.1016/j.biomaterials.2018.08.019 (2018).
- 7 Menter, D. G. *et al.* Platelet "first responders" in wound response, cancer, and metastasis. *Cancer metastasis reviews* (2017).
- 8 Estcourt, L. J. *et al.* Guidelines for the use of platelet transfusions. *Br J Haematol* **176**, 365-394, doi:10.1111/bjh.14423 (2017).
- 9 Birchall, J., New, H. & Cowan, K. *Appropriate use of Platelets across blood groups*, <[http://hospital.blood.co.uk/media/28910/appropriate-use-of-platelets-across-blood-groups-final-1-2 .pdf](http://hospital.blood.co.uk/media/28910/appropriate-use-of-platelets-across-blood-groups-final-1-2.pdf)> (2017).
- 10 Stanworth, S. J., Navarrete, C., Estcourt, L. & Marsh, J. Platelet refractoriness--practical approaches and ongoing dilemmas in patient management. *Br J Haematol* **171**, 297-305, doi:10.1111/bjh.13597 (2015).
- 11 Kickler, T., Kennedy, S. D. & Braine, H. G. Alloimmunization to platelet-specific antigens on glycoproteins IIb-IIIa and Ib/IX in multiply transfused thrombocytopenic patients. *Transfusion* **30**, 622-625 (1990).
- 12 Kiefel, V., König, C., Kroll, H. & Santoso, S. Platelet alloantibodies in transfused patients. *Transfusion* **41**, 766-770 (2001).
- 13 Quillen, K. *et al.* Screening plateletpheresis donors for HLA antibodies on two high-throughput platforms and correlation with recipient outcome. *Transfusion* **51**, 504-510, doi:10.1111/j.1537-2995.2010.02874.x (2011).
- 14 Dutcher, J. P., Schiffer, C. A., Aisner, J. & Wiernik, P. H. Long-term follow-up patients with leukemia receiving platelet transfusions: identification of a large group of patients who do not become alloimmunized. *Blood* **58**, 1007-1011 (1981).
- 15 Wright, J. The origin and nature of blood platelets. *Boston Med Surg J* **154**, 643-645 (1906).

- 16 Nakeff, A. & Maat, B. Separation of megakaryocytes from mouse bone marrow by velocity sedimentation. *Blood* **43**, 591-595 (1974).
- 17 Sola-Visner, M. C., Christensen, R. D., Hutson, A. D. & Rimsza, L. M. Megakaryocyte size and concentration in the bone marrow of thrombocytopenic and nonthrombocytopenic neonates. *Pediatr Res* **61**, 479-484, doi:10.1203/pdr.0b013e3180332c18 (2007).
- 18 Machlus, K. R. & Italiano, J. E. The incredible journey: From megakaryocyte development to platelet formation. *J Cell Biol* **201**, 785-796, doi:10.1083/jcb.201304054 (2013).
- 19 Sugimoto, N. & Eto, K. Platelet production from induced pluripotent stem cells. *J Thromb Haemost* **15**, 1717-1727, doi:10.1111/jth.13736 (2017).
- 20 Richardson, J. L., Shivdasani, R. A., Boers, C., Hartwig, J. H. & Italiano, J. E. Mechanisms of organelle transport and capture along proplatelets during platelet production. *Blood* **106**, 4066-4075, doi:10.1182/blood-2005-06-2206 (2005).
- 21 Brown, E., Carlin, L. M., Nerlov, C., Lo Celso, C. & Poole, A. W. Multiple membrane extrusion sites drive megakaryocyte migration into bone marrow blood vessels. *Life Sci Alliance* **1**, doi:10.26508/lsa.201800061 (2018).
- 22 Schmitz, N. *et al.* Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. *Lancet* **347**, 353-357 (1996).
- 23 Körbling, M. & Freireich, E. J. Twenty-five years of peripheral blood stem cell transplantation. *Blood* **117**, 6411-6416, doi:10.1182/blood-2010-12-322214 (2011).
- 24 Kumar, P. S., Chandrasekhar, C., Srikanth, L. & Sarma, P. V. G. K. In vitro large scale production of megakaryocytes to functional platelets from human hematopoietic stem cells. *Biochem Biophys Res Commun* **505**, 168-175, doi:10.1016/j.bbrc.2018.09.090 (2018).
- 25 Feng, Q. *et al.* Scalable generation of universal platelets from human induced pluripotent stem cells. *Stem cell reports* **3**, 817-831 (2014).
- 26 Mills, J. A., Paluru, P., Weiss, M. J., Gadue, P. & French, D. L. Hematopoietic differentiation of pluripotent stem cells in culture. *Methods Mol Biol* **1185**, 181-194, doi:10.1007/978-1-4939-1133-2_12 (2014).
- 27 Börger, A.-K. *et al.* Generation of HLA-universal iPSCs-derived megakaryocytes and platelets for survival under refractoriness conditions. *Molecular medicine (Cambridge, Mass.)* **22** (2016).
- 28 Eto, K. *et al.* Megakaryocytes derived from embryonic stem cells implicate CalDAG-GEFI in integrin signaling. *Proc Natl Acad Sci U S A* **99**, 12819-12824, doi:10.1073/pnas.202380099 (2002).
- 29 Gaur, M. *et al.* Megakaryocytes derived from human embryonic stem cells: a genetically tractable system to study megakaryocytopoiesis and integrin function. *J Thromb Haemost* **4**, 436-442, doi:10.1111/j.1538-7836.2006.01744.x (2006).
- 30 Takayama, N. *et al.* Generation of functional platelets from human embryonic stem cells in vitro via ES-sacs, VEGF-promoted structures that concentrate hematopoietic progenitors. *Blood* **111**, 5298-5306, doi:10.1182/blood-2007-10-117622 (2008).
- 31 Lu, S. J. *et al.* Platelets generated from human embryonic stem cells are functional in vitro and in the microcirculation of living mice. *Cell Res* **21**, 530-545, doi:10.1038/cr.2011.8 (2011).

- 32 Pick, M., Azzola, L., Osborne, E., Stanley, E. G. & Elefanty, A. G. Generation of megakaryocytic progenitors from human embryonic stem cells in a feeder- and serum-free medium. *PLoS One* **8**, e55530, doi:10.1371/journal.pone.0055530 (2013).
- 33 Takayama, N. *et al.* Transient activation of c-MYC expression is critical for efficient platelet generation from human induced pluripotent stem cells. *J Exp Med* **207**, 2817-2830, doi:10.1084/jem.20100844 (2010).
- 34 Elcheva, I. *et al.* Direct induction of haematoendothelial programs in human pluripotent stem cells by transcriptional regulators. *Nat Commun* **5**, 4372, doi:10.1038/ncomms5372 (2014).
- 35 Nakamura, S. *et al.* Expandable megakaryocyte cell lines enable clinically applicable generation of platelets from human induced pluripotent stem cells. *Cell Stem Cell* **14**, 535-548, doi:10.1016/j.stem.2014.01.011 (2014).
- 36 Liu, L., Andrews, L. G. & Tollefsbol, T. O. Loss of the human polycomb group protein BMI1 promotes cancer-specific cell death. *Oncogene* **25**, 4370-4375, doi:10.1038/sj.onc.1209454 (2006).
- 37 Moreau, T. *et al.* Large-scale production of megakaryocytes from human pluripotent stem cells by chemically defined forward programming. *Nature communications* **7**, 11208 (2016).
- 38 Shin, J.-W., Swift, J., Spinler, K. R. & Discher, D. E. Myosin-II inhibition and soft 2D matrix maximize multinucleation and cellular projections typical of platelet-producing megakaryocytes. *Proceedings of the National Academy of Sciences of the United States of America* **108**, 11458-11463 (2011).
- 39 Ito, Y. *et al.* Turbulence Activates Platelet Biogenesis to Enable Clinical Scale Ex Vivo Production. *Cell* **174**, 636-648.e618, doi:10.1016/j.cell.2018.06.011 (2018).
- 40 Thon, J. N. *et al.* Platelet bioreactor-on-a-chip. *Blood* **124**, 1857-1867 (2014).
- 41 Di Buduo, C. A. *et al.* Modular flow chamber for engineering bone marrow architecture and function. *Biomaterials* **146**, 60-71, doi:10.1016/j.biomaterials.2017.08.006 (2017).
- 42 Tozzi, L. *et al.* Multi-channel silk sponge mimicking bone marrow vascular niche for platelet production. *Biomaterials* **178**, 122-133, doi:10.1016/j.biomaterials.2018.06.018 (2018).
- 43 Brown, C. J. & Navarrete, C. V. Clinical relevance of the HLA system in blood transfusion. *Vox sanguinis* **101**, 93-105 (2011).
- 44 Lanier, L. L. Up on the tightrope: natural killer cell activation and inhibition. *Nat Immunol* **9**, 495-502, doi:10.1038/ni1581 (2008).
- 45 Gras, C. *et al.* HLA-universal platelet transfusions prevent platelet refractoriness in a mouse model. *Hum Gene Ther* **24**, 1018-1028, doi:10.1089/hum.2013.074 (2013).
- 46 Figueiredo, C. *et al.* Generation of HLA-deficient platelets from hematopoietic progenitor cells. *Transfusion* **50**, 1690-1701, doi:10.1111/j.1537-2995.2010.02644.x (2010).
- 47 Figueiredo, C. *et al.* MHC universal cells survive in an allogeneic environment after incompatible transplantation. *Biomed Res Int* **2013**, 796046, doi:10.1155/2013/796046 (2013).
- 48 Ljunggren, H. G. & Kärre, K. In search of the 'missing self': MHC molecules and NK cell recognition. *Immunol Today* **11**, 237-244 (1990).
- 49 Braud, V. M. *et al.* HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. *Nature* **391**, 795-799, doi:10.1038/35869 (1998).

- 50 Borrego, F., Ulbrecht, M., Weiss, E. H., Coligan, J. E. & Brooks, A. G. Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. *J Exp Med* **187**, 813-818 (1998).
- 51 Lee, N. *et al.* HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. *Proc Natl Acad Sci U S A* **95**, 5199-5204 (1998).
- 52 Weiss, E. H. *et al.* HLA-E/human beta2-microglobulin transgenic pigs: protection against xenogeneic human anti-pig natural killer cell cytotoxicity. *Transplantation* **87**, 35-43, doi:10.1097/TP.0b013e318191c784 (2009).
- 53 Zhao, L., Teklemariam, T. & Hantash, B. M. Heterologous expression of mutated HLA-G decreases immunogenicity of human embryonic stem cells and their epidermal derivatives. *Stem Cell Res* **13**, 342-354, doi:10.1016/j.scr.2014.08.004 (2014).
- 54 Geraghty, D. E., Koller, B. H. & Orr, H. T. A human major histocompatibility complex class I gene that encodes a protein with a shortened cytoplasmic segment. *Proc Natl Acad Sci U S A* **84**, 9145-9149 (1987).
- 55 Rouas-Freiss, N., Marchal, R. E., Kirszenbaum, M., Dausset, J. & Carosella, E. D. The alpha1 domain of HLA-G1 and HLA-G2 inhibits cytotoxicity induced by natural killer cells: is HLA-G the public ligand for natural killer cell inhibitory receptors? *Proc Natl Acad Sci U S A* **94**, 5249-5254 (1997).
- 56 Herndler-Brandstetter, D. *et al.* Humanized mouse model supports development, function, and tissue residency of human natural killer cells. *Proc Natl Acad Sci U S A* **114**, E9626-E9634, doi:10.1073/pnas.1705301114 (2017).
- 57 Merkle, F. T. *et al.* Human pluripotent stem cells recurrently acquire and expand dominant negative P53 mutations. *Nature* **545**, 229-233, doi:10.1038/nature22312 (2017).
- 58 Amps, K. *et al.* Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage. *Nat Biotechnol* **29**, 1132-1144, doi:10.1038/nbt.2051 (2011).
- 59 Baker, D. *et al.* Detecting Genetic Mosaicism in Cultures of Human Pluripotent Stem Cells. *Stem Cell Reports* **7**, 998-1012, doi:10.1016/j.stemcr.2016.10.003 (2016).
- 60 Van Loo, P. *et al.* Analyzing cancer samples with SNP arrays. *Methods Mol Biol* **802**, 57-72, doi:10.1007/978-1-61779-400-1_4 (2012).
- 61 Mali, P. *et al.* CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. *Nature biotechnology* **31**, 833-838 (2013).
- 62 Kim, S., Kim, D., Cho, S. W., Kim, J. & Kim, J.-S. Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. *Genome research* **24**, 1012-1019 (2014).
- 63 Thon, J. N., Medvetz, D. A., Karlsson, S. M. & Italiano, J. E. Road blocks in making platelets for transfusion. *Journal of thrombosis and haemostasis : JTH* **13 Suppl 1**, S55-S62 (2015).
- 64 Yagyu, S., Hoyos, V., Del Bufalo, F. & Brenner, M. K. An Inducible Caspase-9 Suicide Gene to Improve the Safety of Therapy Using Human Induced Pluripotent Stem Cells. *Mol Ther* **23**, 1475-1485, doi:10.1038/mt.2015.100 (2015).
- 65 Japan Times. *Blood transfusions with iPS cells OK'd by Japanese health ministry*, <<https://www.japantimes.co.jp/news/2018/09/22/national/science-health/japan-approves-blood-transfusions-including-platelets-ips-cells/> - .XI-KEi2cYdQ> (2018).

- 66 Pulecio, J. *et al.* Direct Conversion of Fibroblasts to Megakaryocyte Progenitors. *Cell Rep* **17**, 671-683, doi:10.1016/j.celrep.2016.09.036 (2016).
- 67 Pavenski, K. *et al.* Efficacy of HLA-matched platelet transfusions for patients with hypoproliferative thrombocytopenia: a systematic review. *Transfusion* **53**, 2230-2242, doi:10.1111/trf.12175 (2013).